103 related articles for article (PubMed ID: 28025004)
1. Mitigation of reactive metabolite formation for a series of 3-amino-2-pyridone inhibitors of Bruton's tyrosine kinase (BTK).
Lou Y; Lopez F; Jiang Y; Han X; Brotherton C; Billedeau R; Gabriel S; Gleason S; Goldstein DM; Hilgenkamp R; Kocer B; Orzechowski L; Tan J; Wovkulich P; Wen B; Fry D; Di Lello P; Chen L; Zhang FJ; Fretland J; Nangia A; Yang T; Owens TD
Bioorg Med Chem Lett; 2017 Feb; 27(3):632-635. PubMed ID: 28025004
[TBL] [Abstract][Full Text] [Related]
2. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
3. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
4. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
[TBL] [Abstract][Full Text] [Related]
5. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
[TBL] [Abstract][Full Text] [Related]
10. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
Yang Y; Shu YZ; Humphreys WG
Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
[TBL] [Abstract][Full Text] [Related]
11. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
[TBL] [Abstract][Full Text] [Related]
12. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.
Zhao X; Xin M; Huang W; Ren Y; Jin Q; Tang F; Jiang H; Wang Y; Yang J; Mo S; Xiang H
Bioorg Med Chem; 2015 Jan; 23(2):348-64. PubMed ID: 25515957
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
[TBL] [Abstract][Full Text] [Related]
15. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
16. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
Kawahata W; Asami T; Fujii I; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
[TBL] [Abstract][Full Text] [Related]
17. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.
Young WB; Barbosa J; Blomgren P; Bremer MC; Crawford JJ; Dambach D; Eigenbrot C; Gallion S; Johnson AR; Kropf JE; Lee SH; Liu L; Lubach JW; Macaluso J; Maciejewski P; Mitchell SA; Ortwine DF; Di Paolo J; Reif K; Scheerens H; Schmitt A; Wang X; Wong H; Xiong JM; Xu J; Yu C; Zhao Z; Currie KS
Bioorg Med Chem Lett; 2016 Jan; 26(2):575-579. PubMed ID: 26675441
[TBL] [Abstract][Full Text] [Related]
18. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
Kawahata W; Asami T; Irie T; Sawa M
Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
[TBL] [Abstract][Full Text] [Related]
20. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
